Breast Cancer
Conditions
Keywords
ER positive, PR positive
Brief summary
Dose dense chemotherapy, which is the term for Adriamycin and Cyclophosphamide (AC) followed by Taxol chemotherapy given every two weeks, is the standard chemotherapy for the treatment of ER+ or PR+ breast cancer. In this trial, the standard chemotherapy is being combined with bevacizumab. Bevacizumab is an antibody which works differently from the way other chemotherapy drugs work. Bevacizumab slows or stops cell growth in cancerous tumors by decreasing the blood supply to the tumors by binding to a substance found on cancer cells called VEGF (vascular endothelial growth factor). Bevacizumab is approved by the FDA for the treatment of colorectal cancer and lung cancer. However, it is not approved for the treatment of breast cancer. Another goal of this research is to determine whether we can develop a way to identify tumors that will respond well to this study treatment.
Detailed description
* To prepare for the surgery that will occur at the end of the study treatment, a small clip will be placed into the tumor area so that the surgeon can locate the site of the tumor at the time of surgery. This is a standard procedure for breast cancer. * During the clip placement, a needle will be inserted into the tumor to measure interstitial fluid pressure (IFP measurement). IFP is done for research purposes to help understand how the tumor responds to the study treatment. * Study treatment will begin with one dose of bevacizumab alone, followed two weeks later by chemotherapy and bevacizumab in eight two-week cycles. The study treatment will be given intravenously in the clinic. * After the first dose of bevacizumab and prior to starting chemotherapy, a needle biopsy of the breast tumor will be performed for research purposes. A second measurement of IFP will also be done at this time. * During the treatment period, tests and procedures will be performed at specified intervals and include the following: research MRI, physical exams, blood tests, urine tests, EKG, and MUGA or ECHO. * Surgery to remove the tumor will occur no less than four weeks after the last dose of Paclitaxel.
Interventions
DRUGDoxorubicin
Standard chemotherapy regimen
DRUGCyclophosphamide
Standard chemotherapy regimen
DRUGPaclitaxel
Standard chemotherapy regimen
DRUGBevacizumab
One intravenous dose given followed 2 weeks later with standard chemotherapy drugs and bevacizumab given intravenously in 8 two-week cycles.
Sponsors
Genentech, Inc.
Massachusetts General Hospital
Brigham and Women's Hospital
New Hampshire Oncology-Hematology PA
Ian E. Krop, MD, PhD
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Documented primary invasive breast cancer by histologic assessment * Tumors must express estrogen (ER) and/or progesterone receptors (PR) by standard immunohistochemical methods. Tumors must be negative for HER2. There must be sufficient sample for further protocol-specified immunohistochemical analysis * Patients must have high risk ER+ or PR+ breast cancer as defined by criteria listed in protocol * 18 year of age or older * Performance status of 0 or 1 by ECOG criteria * Use of an effective means of contraception in subjects of childbearing potential * Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to starting therapy. * Patients taking exogenous sex-steroid hormone treatments for any reason at the time of diagnosis must discontinue all hormonal treatments at least 2 weeks prior to enrollment * Patients must have preoperative treatment within 60 days of initial diagnosis of breast cancer * No other malignancy that requires on-going treatment * Normal organ function as outlined in the protocol
Exclusion criteria
* Prior cytotoxic chemotherapy or radiation for the current breast cancer * Patients with inflammatory breast cancer * HER2 positive disease defined as HER2-amplified by FISH or IHC 3+. HER2 2+ must be negative by FISH * Known metastatic (Stage IV) disease * Other investigational agents within 4 weeks prior to the start of study treatment * Life expectancy of less than 6 months * Peripheral neuropathy greater than or equal to grade 2 * Inadequately controlled hypertension * Any prior history of hypertensive crisis or hypertensive encephalopathy * NYHA grade II or greater congestive heart failure * History of prior myocardial infarction * History of unstable angina within 12 months prior to study enrollment * Any history of stroke or transient ischemic attack at any time * Known CNS disease * Significant vascular disease * Symptomatic peripheral vascular disease * Evidence of significant bleeding within 6 months of study; any serious non-healing wound, skin ulcers, or bone fracture; any abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within the past 6 months; any major surgical procedure within 28 days prior to randomization or anticipation of need for major surgery during course of study. * Known HIV positive * Unwilling to undergo pretreatment biopsy and consent to acquisition of archival tissue * Pregnant of lactating * Known hypersensitivity to any component of bevacizumab
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pathologic Complete Response Rate After Preoperative Therapy in This Patient Population. | 3 Years | Pathological Complete response is defined as complete disappearance of invasive tumor in the breast at the time of surgery |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Decrease in Interstitial Fluid Pressure. | 3 years | To determine if bevacizumab monotherapy results in a decrease in interstitial fluid pressure |
Countries
United States
Participant flow
Recruitment details
Study was activated on 10/17/2007 and Closed to accrual on 7/1/2011.
Participants by arm
| Arm | Count |
|---|---|
| HR+, HER2- Patients with Hormone Receptor Positive, HER2 negative Breast Cancer. A single dose of Bevacizumab 10mg/kg, followed two weeks later by Adriamycin60 mg/m2 and Cyclophosphamide 600 mg/m2 with Bevacizumab 10mg/kg every 2 weeks x4, followed by Taxol 175 mg/m2 with Bevacizumab 10 mg/kg every 2 weeks x3, followed by Taxol 175 mg/m2 x1. | 84 |
| Triple Negative Breast Cancer Cohort Hormone receptor negative, HER2 negative Cohort. Receive same drug protocol as Arm A. | 20 |
| Total | 104 |
Baseline characteristics
| Characteristic | HR+, HER2- | Triple Negative Breast Cancer Cohort | Total |
|---|---|---|---|
| Age, Continuous | 47.5 years | 47.5 years | 47.5 years |
| Region of Enrollment United States | 84 participants | 20 participants | 104 participants |
| Sex: Female, Male Female | 84 Participants | 20 Participants | 104 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 104 / 104 |
| serious Total, serious adverse events | 4 / 104 |
Outcome results
Primary
Pathologic Complete Response Rate After Preoperative Therapy in This Patient Population.
Pathological Complete response is defined as complete disappearance of invasive tumor in the breast at the time of surgery
Time frame: 3 Years
Population: Participants who met all study eligibility criteria and signed informed consent.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| HR+, HER2- | Pathologic Complete Response Rate After Preoperative Therapy in This Patient Population. | 8 percentage of participants |
| Triple Negative Breast Cancer Cohort | Pathologic Complete Response Rate After Preoperative Therapy in This Patient Population. | 44 percentage of participants |
Secondary
Decrease in Interstitial Fluid Pressure.
To determine if bevacizumab monotherapy results in a decrease in interstitial fluid pressure
Time frame: 3 years
Population: This represents the number of patients with paired IFP measurements from day 0 and day 14
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| HR+, HER2- | Decrease in Interstitial Fluid Pressure. | 0.70 mm Hg |
| Triple Negative Breast Cancer Cohort | Decrease in Interstitial Fluid Pressure. | 1.04 mm Hg |